vs

Side-by-side financial comparison of KORN FERRY (KFY) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

KORN FERRY is the larger business by last-quarter revenue ($729.8M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 9.9%, a 24.5% gap on every dollar of revenue. On growth, KORN FERRY posted the faster year-over-year revenue change (7.0% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 3.8%).

Korn Ferry is a management consulting firm headquartered in Los Angeles, California. It was founded in 1969 and as of 2019, operates in 111 offices in 53 countries and employs 8,198 people worldwide. Korn Ferry operates through four business segments: Consulting, Digital, Executive Search, Recruitment Process Outsourcing and Professional Search.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

KFY vs RPRX — Head-to-Head

Bigger by revenue
KFY
KFY
1.2× larger
KFY
$729.8M
$622.0M
RPRX
Growing faster (revenue YoY)
KFY
KFY
+2.2% gap
KFY
7.0%
4.8%
RPRX
Higher net margin
RPRX
RPRX
24.5% more per $
RPRX
34.4%
9.9%
KFY
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
3.8%
KFY

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
KFY
KFY
RPRX
RPRX
Revenue
$729.8M
$622.0M
Net Profit
$72.4M
$214.2M
Gross Margin
Operating Margin
13.5%
62.4%
Net Margin
9.9%
34.4%
Revenue YoY
7.0%
4.8%
Net Profit YoY
19.1%
2.9%
EPS (diluted)
$1.36
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KFY
KFY
RPRX
RPRX
Q4 25
$729.8M
$622.0M
Q3 25
$715.5M
$609.3M
Q2 25
$719.8M
$578.7M
Q1 25
$676.5M
$568.2M
Q4 24
$682.0M
$593.6M
Q3 24
$682.8M
$564.7M
Q2 24
$699.9M
$537.3M
Q1 24
$676.9M
$568.0M
Net Profit
KFY
KFY
RPRX
RPRX
Q4 25
$72.4M
$214.2M
Q3 25
$66.6M
$288.2M
Q2 25
$64.2M
$30.2M
Q1 25
$58.4M
$238.3M
Q4 24
$60.8M
$208.2M
Q3 24
$62.6M
$544.0M
Q2 24
$65.2M
$102.0M
Q1 24
$59.1M
$4.8M
Operating Margin
KFY
KFY
RPRX
RPRX
Q4 25
13.5%
62.4%
Q3 25
11.7%
70.1%
Q2 25
14.5%
36.3%
Q1 25
11.6%
94.0%
Q4 24
12.8%
60.9%
Q3 24
11.1%
Q2 24
11.9%
50.2%
Q1 24
7.4%
-13.0%
Net Margin
KFY
KFY
RPRX
RPRX
Q4 25
9.9%
34.4%
Q3 25
9.3%
47.3%
Q2 25
8.9%
5.2%
Q1 25
8.6%
41.9%
Q4 24
8.9%
35.1%
Q3 24
9.2%
96.3%
Q2 24
9.3%
19.0%
Q1 24
8.7%
0.8%
EPS (diluted)
KFY
KFY
RPRX
RPRX
Q4 25
$1.36
$0.49
Q3 25
$1.26
$0.67
Q2 25
$1.19
$0.07
Q1 25
$1.10
$0.55
Q4 24
$1.14
$0.46
Q3 24
$1.17
$1.21
Q2 24
$1.25
$0.23
Q1 24
$1.13
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KFY
KFY
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$801.1M
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$1.9B
$9.7B
Total Assets
$3.7B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KFY
KFY
RPRX
RPRX
Q4 25
$801.1M
$618.7M
Q3 25
$721.1M
$938.9M
Q2 25
$1.0B
$631.9M
Q1 25
$820.0M
$1.1B
Q4 24
$735.5M
$929.0M
Q3 24
$674.0M
$950.1M
Q2 24
$983.7M
$1.8B
Q1 24
$782.5M
$843.0M
Total Debt
KFY
KFY
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
KFY
KFY
RPRX
RPRX
Q4 25
$1.9B
$9.7B
Q3 25
$1.9B
$9.6B
Q2 25
$1.9B
$9.5B
Q1 25
$1.8B
$9.8B
Q4 24
$1.8B
$10.3B
Q3 24
$1.8B
$10.3B
Q2 24
$1.7B
$9.8B
Q1 24
$1.7B
$9.9B
Total Assets
KFY
KFY
RPRX
RPRX
Q4 25
$3.7B
$19.6B
Q3 25
$3.6B
$19.3B
Q2 25
$3.9B
$18.3B
Q1 25
$3.6B
$17.6B
Q4 24
$3.5B
$18.2B
Q3 24
$3.4B
$18.0B
Q2 24
$3.7B
$17.7B
Q1 24
$3.6B
$16.1B
Debt / Equity
KFY
KFY
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KFY
KFY
RPRX
RPRX
Operating Cash FlowLast quarter
$121.4M
$827.1M
Free Cash FlowOCF − Capex
$100.7M
FCF MarginFCF / Revenue
13.8%
Capex IntensityCapex / Revenue
2.8%
Cash ConversionOCF / Net Profit
1.68×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$272.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KFY
KFY
RPRX
RPRX
Q4 25
$121.4M
$827.1M
Q3 25
$-237.4M
$702.6M
Q2 25
$255.8M
$364.0M
Q1 25
$213.7M
$596.1M
Q4 24
$122.0M
$742.5M
Q3 24
$-227.2M
$703.6M
Q2 24
$261.9M
$658.2M
Q1 24
$164.0M
$664.6M
Free Cash Flow
KFY
KFY
RPRX
RPRX
Q4 25
$100.7M
Q3 25
$-260.0M
Q2 25
$235.5M
Q1 25
$196.4M
Q4 24
$107.7M
Q3 24
$-237.7M
Q2 24
$250.0M
Q1 24
$152.3M
FCF Margin
KFY
KFY
RPRX
RPRX
Q4 25
13.8%
Q3 25
-36.3%
Q2 25
32.7%
Q1 25
29.0%
Q4 24
15.8%
Q3 24
-34.8%
Q2 24
35.7%
Q1 24
22.5%
Capex Intensity
KFY
KFY
RPRX
RPRX
Q4 25
2.8%
Q3 25
3.2%
Q2 25
2.8%
Q1 25
2.6%
Q4 24
2.1%
Q3 24
1.5%
Q2 24
1.7%
Q1 24
1.7%
Cash Conversion
KFY
KFY
RPRX
RPRX
Q4 25
1.68×
3.86×
Q3 25
-3.56×
2.44×
Q2 25
3.98×
12.06×
Q1 25
3.66×
2.50×
Q4 24
2.01×
3.57×
Q3 24
-3.63×
1.29×
Q2 24
4.02×
6.45×
Q1 24
2.78×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KFY
KFY

Industrial$234.0M32%
Technology Service$104.5M14%
RPO$92.3M13%
Digital$91.2M13%
Consumer Goods$85.0M12%
Executive Search EMEA$52.2M7%
Education Non Profit And General$43.2M6%
Executive Search Asia Pacific$24.3M3%
Reimbursed Out Of Pocket Engagement Expenses$8.1M1%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons